Enramycin cuts diarrhea, but shifts gut ecology in weaned rabbits

A new rabbit nutrition study suggests enramycin may offer a familiar tradeoff: less diarrhea in the short term, but measurable changes in the gut environment that could matter longer term. Published September 3, 2026, in Animals, the paper used integrated metagenomic and untargeted metabolomic analyses to look beyond visible production outcomes and into how the drug reshaped the colon in weaned rabbits. (mdpi.com)

That broader lens is important because antimicrobial use in rabbits has long sat at the intersection of enteric disease control, production pressure, and stewardship concerns. Prior rabbit studies have shown that in-feed antibiotics can reduce diarrhea during vulnerable post-weaning periods, while other work has found that removing antibiotic supplementation doesn't always worsen microbiota balance or performance, depending on the line and management system. At the same time, rabbit medicine has a well-established concern about gut sensitivity and dysbiosis, making microbiome-level effects especially relevant. (frontiersin.org)

In the new study, investigators enrolled 60 weaned rabbits and randomized them to a control group or an enramycin group receiving 60 mg/kg in feed for 14 days. Across the full study population, enramycin reduced diarrhea incidence without significantly changing body-weight development, organ indices, or mortality. For deeper analysis, the team performed matched colonic metagenomics and untargeted metabolomics on six randomly selected surviving rabbits per group that had no recorded diarrhea, allowing them to focus on ecological changes not explained simply by overt illness. (mdpi.com)

Those analyses showed that alpha diversity was unchanged, but community structure shifted significantly. The enramycin group had lower Verrucomicrobiota, Akkermansia, and Alistipes, and higher Cyanobacteria and Avigastranaerophilus. The metabolomics arm identified 332 features meeting the study's screening criteria, including 143 upregulated and 189 downregulated metabolites, with pathway signals in phenylpropanoid biosynthesis and arachidonic acid metabolism. Resistome analysis also found changes in signatures related to streptothricin, aminoglycosides, and glycopeptides. The authors conclude that enramycin's benefits on diarrhea need to be weighed against these broader ecological effects. (mdpi.com)

Outside this paper, the stewardship context is easy to see. FDA says approved animal drugs are tracked through the Green Book and describes antimicrobial oversight as part of its broader animal-drug regulatory framework. FDA stewardship materials also emphasize using medically important antimicrobials only when necessary and under veterinary oversight. While this rabbit study was conducted in China and doesn't address a U.S. label change or regulatory action, its findings land in a policy environment that increasingly asks veterinarians and producers to justify antimicrobial exposure with more than just short-term performance gains. (fda.gov)

Why it matters: For veterinary professionals, especially those working with rabbits, small herbivores, or food-animal antimicrobial programs, the study reinforces that clinical outcomes can miss important biologic shifts. A rabbit may have less diarrhea and still show meaningful remodeling of microbial and metabolic pathways, along with resistance-gene changes. That doesn't make enramycin categorically good or bad, but it does strengthen the case for more precise decisions on dose, duration, and case selection, and for comparing antimicrobial approaches with nutrition, management, or other alternatives. It also offers a useful model for future rabbit research: pairing clinical endpoints with microbiome and metabolome data may give a more realistic picture of intervention effects than growth and morbidity data alone. (mdpi.com)

What to watch: The key follow-up questions are whether these microbiome and metabolome changes persist after withdrawal, whether lower or shorter dosing changes the risk-benefit profile, and whether non-antibiotic strategies can deliver similar diarrhea control with less ecological disruption. The authors specifically point to dose-response, withdrawal, and alternative-intervention studies as the logical next phase. (mdpi.com)